If we didn't have so much going good right now, we
Post# of 30025
(Total Views: 488)
Posted On: 03/06/2020 2:24:21 PM
.jpg)
If we didn't have so much going good right now, we'd be getting massacred along with the market. The fact that financing is still going through is huge. Bring on the Lympro 2 results and get that NASDAQ lisiting for TODOS going. Anavex (yes the same from 2016?) will have results this Spring from the trial we might have helped them with long ago. So we can still fit into the next one if they're successful.
For whomever has concerns about Hemp/bio combo. I share them. But step back and look at the synergy too. Weed makes money and arguably does little societal good. Biotech makes no money, but def does societal good. That's a good argument for combination even if the venn diagram feels a little forced. In terms of this investment, what's relevant is that we solidify the market's expectation of us getting that payoff and we now have cash flow now with hempori, promised cash flow in the future with royalties, a promised payoff in 2022, a potential huge value/cash influx to address cap inbalances with todos, and with elto still unsigned, maybe we have a shot at something else. Good times around here still, but we are running up to another Spring credit crunch.
For whomever has concerns about Hemp/bio combo. I share them. But step back and look at the synergy too. Weed makes money and arguably does little societal good. Biotech makes no money, but def does societal good. That's a good argument for combination even if the venn diagram feels a little forced. In terms of this investment, what's relevant is that we solidify the market's expectation of us getting that payoff and we now have cash flow now with hempori, promised cash flow in the future with royalties, a promised payoff in 2022, a potential huge value/cash influx to address cap inbalances with todos, and with elto still unsigned, maybe we have a shot at something else. Good times around here still, but we are running up to another Spring credit crunch.
(1)
(0)